General Manager of Novo Nordisk Indonesia, Sandeep Sur, accepting the award

For the second straight year, the global research company Frost & Sullivan has named Novo Nordisk Indonesia the Diabetes CSR Company of the Year. The acknowledgement recognises the company’s commitment and collaboration to improve care for the six million people with diabetes living in major cities across Indonesia[1].

“The largest and fastest growing prevalence of diabetes is taking place in urban areas,” said Sandeep Sur, Vice President and General Manager, Novo Nordisk Indonesia. “We cannot solve this challenge alone and our partnerships with likeminded stakeholders are how we are making a difference.”

In 2012, Novo Nordisk Indonesia initiated a partnership with the Indonesian Minister of Health to address the diabetes challenge in Indonesia. In 2013, a case study, the Blueprint for Change, identified the impact of urbanisation on health as the leading factor of increasing diabetes prevalence in Indonesia.

The company expanded the partnership with five provincial governments to accelerate actions to change diabetes. One of the memorandums of understanding was signed with the Jakarta Ministry of Health to develop the Jakarta Diabetes Roadmap to combat urban diabetes. The roadmap addresses key challenges, practical solutions, and concrete actions that will serve to reduce the prevalence of urban diabetes in Jakarta and Indonesia at large. The programme covers public awareness activities, capacity building for health workers, and supporting diabetes clinics.

“Our goal is to change diabetes,” says Sandeep. “Improving diabetes awareness and investing in diabetes education for all doctors, nurses and patients is how we will reach it – together!”

In the award report, Frost & Sullivan states:

“By creating awareness and working with other stakeholders, Novo Nordisk is committed towards investing in the country in the long term by addressing the gap in healthcare system.”

The award was presented to Sandeep Sur, Vice President and General Manager, Novo Nordisk Indonesia in Jakarta on 1 October 2015.

About the Best Practice Awards

Frost & Sullivan’s Best Practices Awards recognise companies throughout a range of regional and global markets for superior leadership, technological innovation, customer service, and strategic product development. Frost & Sullivan's industry analyst team benchmarks market participants and measures their performance through independent, primary interviews, and secondary industry research in order to evaluate and identify best practices

Read more about the Frost & Sullivan Best Practice Awards

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has also given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

Read more about Novo Nordisk’s Triple Bottom Line approach to business

[1] International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas

Novo Nordisk

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.

More from Novo Nordisk